References
- Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114(Suppl. 1): Abstract 1126.
- Apperley JF. Management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1116–1128.
- Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
- Schaffer LG, Slovack ML, Campbell LJ, editors. ISCN 2009: International system of human cytogenetic nomenclature. Basel: S. Karger; 2009.
- Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374–7379.
- Mancini M, Nanni M, Sirleto P, et al. GIMEMA study group. Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH). Hematol J 2001;2:54–60.
- Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232–240.
- Gaiger A, Henn T, Horth E, et al. Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995;86:2371–2378.
- Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758–1766.
- Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
- Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190–2196.
- Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005;65:8912–8919.
- Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003;40:69–79.
- Gadzicki D, von Neuhoff N, Steinemann D, et al. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet Cytogenet 2005;159:164–167.
- Szych CM, Liesveld JL, Iqbal MA, et al. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-[?tjl=20mm]	[?tjl]resistant patients. Cancer Genet Cytogenet 2007;174:132–137.